Trials / Terminated
TerminatedNCT04684654
BMS-986325 in Healthy Participants and Participants With Primary Sjögren's Syndrome
A Double-Blind, Placebo-Controlled, Randomized, Single and Multiple Dose Study on the Safety, Pharmacokinetics, and Exploratory Pharmacodynamics of Subcutaneous and Intravenous BMS-986325 Administration in Healthy Participants and Participants With Primary Sjögren's Syndrome
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 118 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, drug levels, and drug effects of BMS-986325 in healthy participants and participants with primary Sjögren's syndrome. The results will guide the future clinical development with BMS-986325.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | BMS-986325 | Specified dose on specified days |
| OTHER | Placebo for BMS-986325 | Specified dose on specified days |
Timeline
- Start date
- 2021-02-16
- Primary completion
- 2023-07-25
- Completion
- 2023-07-25
- First posted
- 2020-12-24
- Last updated
- 2023-08-23
Locations
2 sites across 2 countries: United States, Germany
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04684654. Inclusion in this directory is not an endorsement.